A user began a 6-month experimental protocol using Modified GRF 1-29 (CJC-1295 no DAC) and GHRP-2. They chose to keep the compounds in separate vials for twice-daily dosing, specifically upon waking while fasting and before bed, to track long-term efficacy without modifying variables.